原文は: “Right now we don't have a great 3rd line drug, but Nexavar seems to work fairly well for some patients after failing Gleevec & Sutent. It has not been looked at in a phase III trial, but there is a fairly long-running phase II trial for which some results have been reported. It seems to have pretty good activity against many of the secondary mutations that cause resistance in most cases. Secondary mutations are more of a problem for people with an exon 11 mutation, and don't happen at all for wild-type patients. So Nexavar might be a better choice for exon 11 patients (when resistant to Gleevec and Sutent) and perhaps is not as good for wild-type (Tasigna may be better there). Exon 9 is probably in-between as they do get secondary mutations, but not as often as exon 11 patients.
Jerry”
┗
[4619]
グリベックとスーテントぞうさん
- 2010/07/01(木) 03:18 -
MAIL HOME